Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$79.29 USD

79.29
1,466,257

-1.20 (-1.49%)

Updated Nov 7, 2024 03:59 PM ET

After-Market: $79.32 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Hold on to Edwards Lifesciences for Now

by Zacks Equity Research

Investors continue to be upbeat about Edwards Lifesciences (EW) owing to its strong segmental growth and robust product demand.

QIAGEN's (QGEN) Selloff Deal With Thermo Fisher Progresses

by Zacks Equity Research

QIAGEN's (QGEN) acquisition deal with Thermo Fisher receives approval from QIAGEN shareholders.

Debanjana Dey headshot

4 Cheap MedTech Stocks Poised to Beat Industry Post-Pandemic

by Debanjana Dey

Here are some MedTech stocks which might be a solid investment option post the coronavirus blues.

Abbott, Tandem Diabetes Seal Deal on Diabetes Management

by Zacks Equity Research

Abbott's (ABT) FreeStyle Libre CGM technology to be integrated with Tandem Diabetes' insulin pumps to enhance diabetes care.

LabCorp's Xcellerate Coronavirus Solution to Aid Clinical R&D

by Zacks Equity Research

This solution by LabCorp (LH) takes the idea from Covance's COVID-19 Operational Recovery Team to better understand the necessities.

Bio-Rad Rides on PCR Test Kits for Coronavirus Amid Cost Woe

by Zacks Equity Research

The uptick in Bio-Rad's (BIO) core PCR and Droplet Digital PCR product revenues is the result of robust demand due to coronavirus testing and related research.

Zacks.com featured highlights include: Keurig Dr Pepper, Hologic, Meritage Homes, Vistra Energy and Sally Beauty

by Zacks Equity Research

Zacks.com featured highlights include: Keurig Dr Pepper, Hologic, Meritage Homes, Vistra Energy and Sally Beauty

HOLX vs. IDXX: Which Stock Is the Better Value Option?

by Zacks Equity Research

HOLX vs. IDXX: Which Stock Is the Better Value Option?

Myriad Genetics' myPath Melanoma Proved Superior Per New Study

by Zacks Equity Research

Myriad Genetics' (MYGN) myPath Melanoma's accuracy to classify skin lesions, termed as indeterminate by standard pathological review, validated by the latest study.

Here's Why You Should Hold on to Illumina Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Illumina (ILMN) backed by its focus on partnerships and robust demand for its products.

Swayta Shah headshot

5 Stocks With Upgraded Broker Ratings to Buy Right Away

by Swayta Shah

By following broker ratings, you can find stocks that are likely to generate impressive returns.

LabCorp Neutralizing Antibody Test to Aid Coronavirus Vaccine R&D

by Zacks Equity Research

The information related to neutralizing antibody test of LabCorp (LH) can also be used for the screening of convalescent plasma for prophylactic and therapeutic use.

Medtronic's DBS System With BrainSense Technology Gets FDA Nod

by Zacks Equity Research

Medtronic's (MDT) first-of-its-kind Percept PC DBS system with the next-generation BrainSense technology clears FDA hurdle, paving the way for data-driven neurostimulation treatment.

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be upbeat about ResMed (RMD) owing to its strong emphasis on product development and consistent high demand for its critical care products.

Tandem Diabetes' Sugarmate Buyout Boosts Digital Offerings

by Zacks Equity Research

Tandem Diabetes (TNDM) expands digital portfolio with the Sugarmate app buyout, paving the way for the company's expansion of diabetes-related products and services ecosystem.

CVS Health Offers Coronavirus Testing for Students, Businesses

by Zacks Equity Research

CVS Health (CVS) is increasing access to COVID-19 testing options as mass unlocking takes place throughout the nation.

Conformis Next-Generation Identity PS Knee System Gets FDA Nod

by Zacks Equity Research

Conformis' (CFMS) latest iTotal Identity PS Knee System clears FDA hurdle, paving the way for providing better patient-specific pre-operative surgical plans.

Moving Average Crossover Alert: Hologic

by Zacks Equity Research

Hologic, Inc. (HOLX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Amedisys Rides on Hospice Arm Expansion Amid Coronavirus Woes

by Zacks Equity Research

Amedisys (AMED) benefits from the recent acquisitions of hospice care providers, Asana Hospice, RoseRock Healthcare and Compassionate Care Hospice.

Medtronic's Evolut TAVI Gets CE Mark for Low-Risk Patients

by Zacks Equity Research

Medtronic's (MDT) Evolut system shows a lower rate of the composite of all-cause death or disabling stroke with TAVI at 30 days.

Zimmer Biomet Adds New Features to mymobility with Apple Watch

by Zacks Equity Research

Zimmer Biomet (ZBH) expands mymobility digital platform by leveraging Apple's ecosystem to enhance patients' post-operative care.

Thermo Fisher Grows on Coronavirus Diagnostic Tests Amid Crisis

by Zacks Equity Research

Thermo Fisher (TMO) is optimistic about ramped up production for its COVID-19 diagnostic test to meet growing global demand.

NuVasive Launches Reline 3D for Pediatric Patients Globally

by Zacks Equity Research

Other than Reline 3D, NuVasive's (NUVA) Reline System portfolio has products like Reline Open, Reline MAS, Reline Trauma and Reline Small Stature.

Here's Why You Should Hold on to NuVasive (NUVA) Stock Now

by Zacks Equity Research

Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as solid international business.

Medtronic Partners Foxconn to Scale Up Ventilator Production

by Zacks Equity Research

Medtronic (MDT) enters into a partnership with Foxconn with an aim of providing 10,000 PB560 ventilators in the United States over the next year amid the pandemic-led surge in demand for the same.